• Home >>
  • Pharmaceuticals and Healthcare >>
  • Oncology Biosimilar Market : Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis and Competitive Analysis 2017 - 2025

Oncology Biosimilar Market : Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis and Competitive Analysis 2017 - 2025

ID: 58928 February, 2018 Region : Global Pages
Covid-19

COVID-19

Understand the influence of COVID-19 on the Oncology Biosimilar Market with our analysts monitoring the situation across the globe.

HC-RD Oncology Biosimilars Market by Drug (monoclonal antibodies, haematopoietic agents and G-CSF), by Diseases (breast cancer, neutropenia, blood cancer,), by Distribution Channel (hospital pharmacies, online pharmacies)-Global Forecast till 2025
Market Synopsis

Biosimilar is biological medicine that is profoundly similar version of already approved biological agent known as originator or reference product and authorized for use in same manifestation as the indicator product. Biosimilar is precisely designed to have particular pharmaceutical active ingredient same as indicator product. The presence of biosimilars facilitates chances of lowering health care expenses as consequence of inherent price competition with the reference product.  Biosimilars in oncology are highly similar to biologics of oncology produced by different prominent pharmaceutical companies and have been officially permitted for treatment of cancer.


The comparatively easy manufacturing of biosimilars and after expiration of many generic products acquiring licence for production of biosimilars  is acting in favour of the global oncology biolsimilars market.  Highly expensive branded biologic oncological drugs will shift the patients towards biosimilars as they are relatively cost-effective and increased prevalence of cancer will help in propelling the market growth in coming future. Nevertheless, regulatory approval demands equivalent analytical and clinical studies to present no clinically meaningful contrast between indicator product and biologics. These stringent criteria might hinder the growth of global oncology market.   Pharmaceutical companies across the globe are aiming to produce biosimilars that can deal with the cancer at different stages providing similar efficacy and potency as indicator product at cheaper cost gives an opportunity to expand the market.


Segmentation
The global oncology biosimilars market is segmented On the basis of drug, disease, distribution channel and geography. Based on drug type the market is separated into monoclonal antibodies, haematopoietic agents and G-CSF. Considering disease the market has been divided into breast cancer, colorectal cancer, neutropenia, blood cancer, non-small cell lung cancer and others. Based on to distribution channel the market is classified into hospital pharmacies, retail pharmacies and online pharmacies. 


Regional Analysis
Considering geography market is analysed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific is anticipated to have strong foothold in the global oncology biosimilars market owing to increased spread of cancer, activities like merger, acquisition in this particular region for development and commercialization of biosimilars. Furthermore European countries such as Spain, Italy, UK, Russia and France are predicted to witness the lucrative growth. Growth of the market in this region is attributed to well established & mature market of biosimlilars, increased geriatric population and soon expiries of biologics that will go off-patent.


Key Players
The prominent players operating in the market are Biocon, Hospira, Sandoz International GmbH, Mylan, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd, Celltrion Inc., STADA Arzneimittel AG and Intas Pharmaceuticals Ltd.


Global Oncology Biosimilars Market Segmentation
By drug Type
 Monoclonal Antibody
 Haematopoietic Agents
 G-CSF(granulocyte colony stimulating factor)


By Disease Condition
 Breast Cancer
 Colorectal Cancer
 Neutropenia
 Blood cancer
 Non-small Cell Lung cancer 
Distribution Channel
 Hospital Pharmacies
 Retail Pharmacies
 Online Pharmacies


By Geography
• North America
 U.S
 Canada
• Europe
 Germany
 UK
 France
 Italy
 Russia
 Spain
 Rest of Europe
• Asia-Pacific
 Japan
 China
 India
 South Korea
 Australia & New Zealand
 Rest of APAC
• LAMEA
 Brazil
 Argentina
 Saudi Arabia
 Rest of LAMEA


Kay Market Players
 Biocon
 Hospira
 Sandoz International GmbH
 Mylan
 Dr. Reddy’s Laboratories Ltd.
 Teva Pharmaceutical Industries Ltd
 Celltrion Inc.
 STADA Arzneimittel AG
 Intas Pharmaceuticals Ltd.

Research Scope
The study for Global Oncology Biosimilars Market will provide market size, estimates and forecast based on the following years: 
 
Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025


The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 
Our analyst implement several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market. 

1. Introduction
1.1. Market Definition
1.2. Market Scope


2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions


3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016 


4. Drug Overview
4.1. Introduction
4.2. Market Size & Forecast, 2015 to 2025
4.2.1. Monoclonal Antibody
4.2.2. Haematopoietic Agents
4.2.3. G-CSF (granulocyte colony stimulating factor)
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


5. Disease Condition Overview
5.1. Introduction
5.2. Market Size & Forecast, 2015 to 2025
5.2.1. Breast Cancer
5.2.2. Colorectal Cancer
5.2.3. Neutropenia
5.2.4. Blood cancer
5.2.5. Non-small Cell Lung cancer 
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


6. Distribution Channel Overview
6.1. Introduction
6.2. Market Size & Forecast, 2015 to 2025
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


7. Regional Overview
7.1. Introduction
7.2. Market Size & Forecast, 2015 to 2025
7.2.1. North America
7.2.1.1. U.S.
7.2.1.2. Canada
7.2.2. Europe
7.2.2.1. Germany
7.2.2.2. UK
7.2.2.3. France
7.2.2.4. Italy
7.2.2.5. Russia
7.2.2.6. Spain
7.2.2.7. Rest of Europe
7.2.3. Asia-Pacific
7.2.3.1. Japan
7.2.3.2. China
7.2.3.3. India
7.2.3.4. South Korea
7.2.3.5. Australia & New Zealand
7.2.3.6. Rest of Asia-Pacific
7.2.4. LAMEA
7.2.4.1. Brazil
7.2.4.2. Argentina
7.2.4.3. Saudi Arabia
7.2.4.4. Rest of LAMEA
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)


8. Manufacturer/ Vendor Profile
8.1. The following attributes will be considered while profiling key manufacturers in this industry: 
8.1.1. Company Overview
8.1.2. Financial Synopsis
8.1.3. Recent Developments
8.1.4. R&D Investments (if any)
8.1.5. Strategy Overview (Analyst Perspective)
8.1.6. Product Portfolio
8.2. Companies Profiled
8.2.1. Biocon
8.2.2. Hospira
8.2.3. Sandoz International GmbH
8.2.4. Mylan
8.2.5. Dr. Reddy’s Laboratories Ltd.
8.2.6. Teva Pharmaceutical Industries Ltd
8.2.7. Celltrion Inc.
8.2.8. STADA Arzneimittel AG
8.2.9. Intas Pharmaceuticals Ltd.
8.2.10. 
 (Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.)

Request COVID-19 Impact Analysis

We understand the economic repercussions of the pandemic and are dedicated towards helping our clients strategize with rapidly changing market scenario,
• Impact of COVID on supply/demand scenario, trade landscape & supply chain
• How market participants are preparing/strategizing to combat the impact
• How does the short-term & long-term scenario for Oncology Biosimilar Market looks like

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




2 + 5 =

 

Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]

Report ID :58928

Published Date :February, 2018

Category :Pharmaceuticals and Healthcare

Pages : Pages

Why Choose Us

  • Lowest Price Guarantee
  • We offer the lowest prices for the listed reports

  • Data Security
  • Your data is safe and secure

  • Vast Report Database
  • We have more than 2 Million reports in our database

  • Client Focused
  • Personalized updates and 24*7 support

  • Trusted Source and Quality
  • We only work with reputable partners providing high quality research and support

  • Market Segmentation
  • We provide alternative views of the market to help you identify where the real opportunities lie

  • Bulk Discounts
  • We offer great discounts on purchase of multiple reports


Every Sample Will Help to Understand

  • Report Structure and Outline
  • Detailed Table of Content (Including List of Tables and Figures)
  • Research Methodology